Professor Lori Laffel
Professor Lori Laffel is Chief of the Pediatric, Adolescent and Young Adult Section and a Senior Investigator/Co-Head of the Section on Clinical, Behavioral and Outcomes Research at the Joslin Diabetes Center, as well as a Professor of Pediatrics at Harvard Medical School. Under Dr. Laffel’s leadership, the pediatric program at Joslin has more than quadrupled in size and is recognised worldwide as a major pediatric diabetes centre for clinical care and research.
Dr. Laffel has been Principal Investigator on multiple NIH and foundation funded grants and the Principal Investigator and Program Director of NIH-funded postdoctoral fellowship and early career development training grants for pediatric endocrinologists entering the field of diabetes research. She has published more than 200 articles in peer reviewed journals. She also has been a member of the advisory board of the International Society of Pediatric and Adolescent Diabetes (ISPAD) and a member of the Clinical Advisory Committee for the JDRF. She is currently a member of the JDRF’s Research Advisory Committee.
She is actively involved with the American Diabetes Association (ADA), as a member of the Boston Leadership Board, a recent past member of the National Board of Directors of the ADA, past member of the National Committee for Professional Practice Guidelines, chair on the ADA’s Working Group on Transitions in Care for Young Adults with Diabetes, and past chair of ADA’s Youth Strategies Committee. She was Co-Chair of the JDRF CGM Study. She was also the co-editor on the recently released ADA-JDRF Sourcebook on Type 1 Diabetes through the Life. She is recipient of the American Diabetes Association’s 2015 Outstanding Physician-Clinician Award, the Greater Boston Chamber of Commerce 2016 Pinnacle Award, and the 2016 University of Miami School of Medicine Hall of Fame Award.
Her research focuses on understanding and overcoming challenges to adherence in patients with diabetes in order to improve glycemic control, biomedical, and psychosocial outcomes; and optimizing use of diabetes technologies, including automated insulin delivery systems.